BRUNO, DANIELE
 Distribuzione geografica
Continente #
AS - Asia 92
EU - Europa 61
NA - Nord America 45
SA - Sud America 27
Totale 225
Nazione #
SG - Singapore 44
US - Stati Uniti d'America 42
IE - Irlanda 31
BR - Brasile 22
CN - Cina 15
HK - Hong Kong 13
RU - Federazione Russa 11
VN - Vietnam 11
IT - Italia 6
BE - Belgio 4
IN - India 3
SE - Svezia 3
AR - Argentina 2
BD - Bangladesh 2
FR - Francia 2
JP - Giappone 2
BZ - Belize 1
CA - Canada 1
DE - Germania 1
DK - Danimarca 1
EC - Ecuador 1
KG - Kirghizistan 1
KZ - Kazakistan 1
MX - Messico 1
NL - Olanda 1
PE - Perù 1
PL - Polonia 1
PY - Paraguay 1
Totale 225
Città #
Dublin 31
Singapore 24
Hong Kong 13
Ashburn 8
Beijing 8
Santa Clara 5
Brussels 4
Ho Chi Minh City 4
Milan 3
Nyköping 3
Rio de Janeiro 3
Thái Nguyên 3
Brasília 2
Dallas 2
New York 2
Pune 2
San Francisco 2
Seattle 2
São Paulo 2
Toyohashi 2
Aarhus 1
Almaty Region 1
Aparecida de Goiânia 1
Araci 1
Barueri 1
Belmopan 1
Bishkek 1
Blumenau 1
Boiling Springs 1
Brooklyn 1
Bình Dương 1
Cariacica 1
Caumont-sur-Durance 1
Caxias do Sul 1
Changsha 1
Chennai 1
Conceição das Pedras 1
Cà Mau 1
Da Nang 1
Goiânia 1
Hanoi 1
Huilong 1
Ivoti 1
La Troncal 1
Lima 1
Los Angeles 1
Mexico City 1
Moscow 1
Munich 1
Natore 1
Neuquén 1
Praia Grande 1
Salto 1
San Antonio 1
San Estanislao 1
San Jose 1
Santana do Livramento 1
Senhor do Bonfim 1
Uberaba 1
Ubá 1
Valle de Anisacate 1
Warsaw 1
Wauseon 1
Zhengzhou 1
Totale 169
Nome #
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis 58
Role of Etiology in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Counterfactual Event-Based Mediation Analysis 54
Clinical Significance of Molecular Subtypes in Western Advanced Gastric Cancer: A Real-World Multicenter Experience 42
Primary versus secondary antiemetic prophylaxis with NK1 receptor antagonists in patients affected by gastrointestinal malignancies and treated with a doublet or triplet combination regimen including oxaliplatin and/or irinotecan plus fluoropyrimidines: A propensity score matched analysis 40
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data 25
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 24
Totale 243
Categoria #
all - tutte 1.723
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.723


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202344 0 0 0 0 1 3 2 6 32 0 0 0
2023/202417 2 1 1 0 2 5 1 2 0 0 0 3
2024/202571 1 1 1 9 0 18 3 0 10 6 10 12
2025/2026111 20 20 30 28 10 3 0 0 0 0 0 0
Totale 243